Close this search box.

Furuta to become CFO at Takeda

ARTICLE | Management Tracks

Plus: IDRx names Kerstein CMO and updates from Transgene, Noetik, Egle and MannKind

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst  

March 27, 2024 11:32 PM UTC

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) announced the retirement of CFO Constantine Saroukos, who will be succeeded on April 1st by Milano Furuta, president of the pharma’s Japan pharma business unit. Saroukos will leave Takeda’s board on June 26, the date of the pharma’s general shareholder meeting. The company has proposed Furuta in its list of 15 candidates for directors.

Cancer play IDRx Inc. hired David Kerstein as CMO. Kerstein previously held CMO roles at Theseus Pharmaceuticals Inc. and Anchiano Therapeutics Ltd…